Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 139

1.

Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors.

Singh S, Moody L, Chan DL, Metz DC, Strosberg J, Asmis T, Bailey DL, Bergsland E, Brendtro K, Carroll R, Cleary S, Kim M, Kong G, Law C, Lawrence B, McEwan A, McGregor C, Michael M, Pasieka J, Pavlakis N, Pommier R, Soulen M, Wyld D, Segelov E; Commonwealth Neuroendocrine Tumour Collaboration (CommNETS) Follow-up Working Group.

JAMA Oncol. 2018 Jul 26. doi: 10.1001/jamaoncol.2018.2428. [Epub ahead of print]

PMID:
30054622
2.

The role of proteomics in the age of immunotherapies.

Hayes SA, Clarke S, Pavlakis N, Howell VM.

Mamm Genome. 2018 Jul 25. doi: 10.1007/s00335-018-9763-6. [Epub ahead of print] Review.

PMID:
30046851
3.

Targeted therapy for metastatic colorectal cancer.

Price TJ, Tang M, Gibbs P, Haller DG, Peeters M, Arnold D, Segelov E, Roy A, Tebbutt N, Pavlakis N, Karapetis C, Burge M, Shapiro J.

Expert Rev Anticancer Ther. 2018 Aug 3:1-16. doi: 10.1080/14737140.2018.1502664. [Epub ahead of print]

PMID:
30019590
4.

Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial.

Li BT, Shen R, Buonocore D, Olah ZT, Ni A, Ginsberg MS, Ulaner GA, Offin M, Feldman D, Hembrough T, Cecchi F, Schwartz S, Pavlakis N, Clarke S, Won HH, Brzostowski EB, Riely GJ, Solit DB, Hyman DM, Drilon A, Rudin CM, Berger MF, Baselga J, Scaltriti M, Arcila ME, Kris MG.

J Clin Oncol. 2018 Jul 10:JCO2018779777. doi: 10.1200/JCO.2018.77.9777. [Epub ahead of print]

PMID:
29989854
5.

ROS1-Rearranged Non-Small-Cell Lung Cancer, Factor V Leiden, and Recurrent Venous Thromboses.

Lee A, Howell VM, Itchins M, Wheeler HR, Pavlakis N.

Clin Lung Cancer. 2018 Jun 5. pii: S1525-7304(18)30135-9. doi: 10.1016/j.cllc.2018.05.015. [Epub ahead of print] No abstract available.

PMID:
29945753
6.

Accreditation Standard Guideline Initiative for Tai Chi and Qigong Instructors and Training Institutions.

Oh B, Yeung A, Klein P, Larkey L, Ee C, Zaslawski C, Knobf T, Payne P, Stener-Victorin E, Lee R, Choi W, Chun M, Bonucci M, Lang HD, Pavlakis N, Boyle F, Clarke S, Back M, Yang P, Wei Y, Guo X, Weng CD, Irwin MR, Elfiky AA, Rosenthal D.

Medicines (Basel). 2018 Jun 8;5(2). pii: E51. doi: 10.3390/medicines5020051.

7.

Using patient-derived xenograft models of colorectal liver metastases to predict chemosensitivity.

Brown KM, Xue A, Julovi SM, Gill AJ, Pavlakis N, Samra JS, Smith RC, Hugh TJ.

J Surg Res. 2018 Jul;227:158-167. doi: 10.1016/j.jss.2018.02.018. Epub 2018 Mar 15.

PMID:
29804848
8.

Pattern of care and survival of anaplastic lymphoma kinase rearranged non-small cell lung cancer (ALK+ NSCLC) in an Australian Metropolitan Tertiary Referral Centre: A retrospective cohort analysis.

Itchins M, Hayes SA, Gill AJ, Cooper W, O'Connell R, Howell VM, Clarke SJ, Pavlakis N.

Asia Pac J Clin Oncol. 2018 Apr 19. doi: 10.1111/ajco.12877. [Epub ahead of print]

PMID:
29675948
9.

External Beam Radiotherapy in the Treatment of Gastroenteropancreatic Neuroendocrine Tumours: A Systematic Review.

Chan DL, Thompson R, Lam M, Pavlakis N, Hallet J, Law C, Singh S, Myrehaug S.

Clin Oncol (R Coll Radiol). 2018 Jul;30(7):400-408. doi: 10.1016/j.clon.2018.03.006. Epub 2018 Mar 31.

PMID:
29615284
10.
11.

Follow-Up for Resected Gastroenteropancreatic Neuroendocrine Tumours: A Practice Survey of the Commonwealth Neuroendocrine Tumour Collaboration (CommNETS) and the North American Neuroendocrine Tumor Society (NANETS).

Chan DL, Moody L, Segelov E, Metz DC, Strosberg JR, Pavlakis N, Singh S.

Neuroendocrinology. 2018;107(1):32-41. doi: 10.1159/000488394. Epub 2018 Mar 14.

PMID:
29539613
12.

Do EGFR tyrosine kinase inhibitors (TKIs) still have a role in EGFR wild-type pre-treated advanced non-small cell lung cancer (NSCLC)?-the shifting paradigm of therapeutics.

Itchins M, Clarke S, Pavlakis N.

Transl Lung Cancer Res. 2018 Feb;7(Suppl 1):S39-S45. doi: 10.21037/tlcr.2018.01.06. No abstract available.

13.

Challenges in chemotherapy delivery: comparison of standard chemotherapy delivery to locoregional vascular mass fluid transfer.

Lane RJ, Khin NY, Pavlakis N, Hugh TJ, Clarke SJ, Magnussen J, Rogan C, Flekser RL.

Future Oncol. 2018 Mar;14(7):647-663. doi: 10.2217/fon-2017-0546. Epub 2018 Mar 7.

14.

Adjuvant therapy for resected colon cancer 2017, including the IDEA analysis.

Tang M, Price TJ, Shapiro J, Gibbs P, Haller DG, Arnold D, Peeters M, Segelov E, Roy A, Tebbutt N, Pavlakis N, Karapetis C, Burge M.

Expert Rev Anticancer Ther. 2018 Apr;18(4):339-349. doi: 10.1080/14737140.2018.1444481. Epub 2018 Mar 1.

PMID:
29478352
15.

Osteoclast inhibitors to prevent bone metastases in men with high-risk, non-metastatic prostate cancer: A systematic review and meta-analysis.

Hayes AR, Brungs D, Pavlakis N.

PLoS One. 2018 Jan 25;13(1):e0191455. doi: 10.1371/journal.pone.0191455. eCollection 2018. Review.

16.

Convergent priorities and tensions: a qualitative study of the integration of complementary and alternative therapies with conventional cancer treatment.

River J, McKenzie H, Levy D, Pavlakis N, Back M, Oh B.

Support Care Cancer. 2018 Jun;26(6):1791-1797. doi: 10.1007/s00520-017-4021-0. Epub 2017 Dec 16.

PMID:
29249059
17.

Patient-reported experience of the impact and burden of neuroendocrine tumors: Oceania patient results from a large global survey.

Leyden J, Pavlakis N, Chan D, Michael M, Clarke S, Khasraw M, Price T.

Asia Pac J Clin Oncol. 2018 Jun;14(3):256-263. doi: 10.1111/ajco.12785. Epub 2017 Nov 6.

PMID:
29105989
18.

Acupuncture in Oncology: The Effectiveness of Acupuncture May Not Depend on Needle Retention Duration.

Oh B, Eade T, Kneebone A, Hruby G, Lamoury G, Pavlakis N, Clarke S, Zaslawski C, Marr I, Costa D, Back M.

Integr Cancer Ther. 2018 Jun;17(2):458-466. doi: 10.1177/1534735417734912. Epub 2017 Nov 2.

19.

Bisphosphonates and other bone agents for breast cancer.

O'Carrigan B, Wong MH, Willson ML, Stockler MR, Pavlakis N, Goodwin A.

Cochrane Database Syst Rev. 2017 Oct 30;10:CD003474. doi: 10.1002/14651858.CD003474.pub4. Review.

PMID:
29082518
20.

Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl.

Anthony L, Ervin C, Lapuerta P, Kulke MH, Kunz P, Bergsland E, Hörsch D, Metz DC, Pasieka J, Pavlakis N, Pavel M, Caplin M, Öberg K, Ramage J, Evans E, Yang QM, Jackson S, Arnold K, Law L, DiBenedetti DB.

Clin Ther. 2017 Nov;39(11):2158-2168. doi: 10.1016/j.clinthera.2017.09.013. Epub 2017 Oct 23.

21.

Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.

van Zandwijk N, Pavlakis N, Kao SC, Linton A, Boyer MJ, Clarke S, Huynh Y, Chrzanowska A, Fulham MJ, Bailey DL, Cooper WA, Kritharides L, Ridley L, Pattison ST, MacDiarmid J, Brahmbhatt H, Reid G.

Lancet Oncol. 2017 Oct;18(10):1386-1396. doi: 10.1016/S1470-2045(17)30621-6. Epub 2017 Sep 1.

PMID:
28870611
22.

Identifying and Prioritizing Gaps in Neuroendocrine Tumor Research: A Modified Delphi Process With Patients and Health Care Providers to Set the Research Action Plan for the Newly Formed Commonwealth Neuroendocrine Tumor Collaboration.

Segelov E, Chan D, Lawrence B, Pavlakis N, Kennecke HF, Jackson C, Law C, Singh S.

J Glob Oncol. 2016 Oct 12;3(4):380-388. doi: 10.1200/JGO.2016.006916. eCollection 2017 Aug.

23.

Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma.

Martin AJ, Gibbs E, Sjoquist K, Pavlakis N, Simes J, Price T, Shannon J, Gill S, Jain V, Liu G, Kannourakis G, Kim YH, Kim JW, Goldstein D; INTEGRATE I investigators.

Gastric Cancer. 2018 May;21(3):473-480. doi: 10.1007/s10120-017-0754-1. Epub 2017 Aug 16.

PMID:
28815316
24.

Treatment of ALK-rearranged non-small cell lung cancer: A review of the landscape and approach to emerging patterns of treatment resistance in the Australian context.

Itchins M, Chia PL, Hayes SA, Howell VM, Gill AJ, Cooper WA, John T, Mitchell P, Millward M, Clarke SJ, Solomon B, Pavlakis N.

Asia Pac J Clin Oncol. 2017 Aug;13 Suppl 3:3-13. doi: 10.1111/ajco.12754. Review.

PMID:
28795492
25.

Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review.

Chan DL, Ferone D, Albertelli M, Pavlakis N, Segelov E, Singh S.

Endocrine. 2017 Sep;57(3):366-375. doi: 10.1007/s12020-017-1360-z. Epub 2017 Jul 19. Review.

PMID:
28726183
26.

Retrospective cohort analysis of neoadjuvant treatment and survival in resectable and borderline resectable pancreatic ductal adenocarcinoma in a high volume referral centre.

Itchins M, Arena J, Nahm CB, Rabindran J, Kim S, Gibbs E, Bergamin S, Chua TC, Gill AJ, Maher R, Diakos C, Wong M, Mittal A, Hruby G, Kneebone A, Pavlakis N, Samra J, Clarke S.

Eur J Surg Oncol. 2017 Sep;43(9):1711-1717. doi: 10.1016/j.ejso.2017.06.012. Epub 2017 Jun 28.

PMID:
28688722
27.

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer.

Chan DLH, Segelov E, Wong RS, Smith A, Herbertson RA, Li BT, Tebbutt N, Price T, Pavlakis N.

Cochrane Database Syst Rev. 2017 Jun 27;6:CD007047. doi: 10.1002/14651858.CD007047.pub2. Review.

PMID:
28654140
28.

Clinical and imaging-based prognostic factors in radioembolisation of liver metastases from colorectal cancer: a retrospective exploratory analysis.

Willowson KP, Hayes AR, Chan DLH, Tapner M, Bernard EJ, Maher R, Pavlakis N, Clarke SJ, Bailey DL.

EJNMMI Res. 2017 Dec;7(1):46. doi: 10.1186/s13550-017-0292-1. Epub 2017 May 23.

29.

Lost in translation: returning germline genetic results in genome-scale cancer research.

Johns AL, McKay SH, Humphris JL, Pinese M, Chantrill LA, Mead RS, Tucker K, Andrews L, Goodwin A, Leonard C, High HA, Nones K, Patch AM, Merrett ND, Pavlakis N, Kassahn KS, Samra JS, Miller DK, Chang DK, Pajic M; Australian Pancreatic Cancer Genome Initiative, Pearson JV, Grimmond SM, Waddell N, Zeps N, Gill AJ, Biankin AV.

Genome Med. 2017 Apr 28;9(1):41. doi: 10.1186/s13073-017-0430-4.

30.

The evolving landscape of treatment for advanced gastric cancer and the role of anti-angiogenic therapy: implications from results of the INTEGRATE study.

Itchins M, Pavlakis N.

Transl Gastroenterol Hepatol. 2017 Apr 7;2:29. doi: 10.21037/tgh.2017.02.02. eCollection 2017. No abstract available.

31.

Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance.

Chan DL, Pavlakis N, Schembri GP, Bernard EJ, Hsiao E, Hayes A, Barnes T, Diakos C, Khasraw M, Samra J, Eslick E, Roach PJ, Engel A, Clarke SJ, Bailey DL.

Theranostics. 2017 Mar 1;7(5):1149-1158. doi: 10.7150/thno.18068. eCollection 2017.

32.

Real-world experience of the feasibility and tolerability of the 2/1 dosing schedule with sunitinib in the treatment of patients with advanced renal cell carcinoma in Australia.

Crumbaker M, Guminski A, Gurney H, Sabanathan D, Wong S, Pavlakis N.

Asia Pac J Clin Oncol. 2018 Apr;14(2):e45-e49. doi: 10.1111/ajco.12686. Epub 2017 Apr 21.

PMID:
28429452
33.

Prognostic and predictive biomarkers in neuroendocrine tumours.

Chan DL, Clarke SJ, Diakos CI, Roach PJ, Bailey DL, Singh S, Pavlakis N.

Crit Rev Oncol Hematol. 2017 May;113:268-282. doi: 10.1016/j.critrevonc.2017.03.017. Epub 2017 Mar 18. Review.

PMID:
28427516
34.

Immune Checkpoint Inhibitors for Brain Metastases.

Tan AC, Heimberger AB, Menzies AM, Pavlakis N, Khasraw M.

Curr Oncol Rep. 2017 Jun;19(6):38. doi: 10.1007/s11912-017-0596-3. Review.

PMID:
28417311
35.

A Longitudinal Investigation of Inflammatory Markers in Colorectal Cancer Patients Perioperatively Demonstrates Benefit in Serial Remeasurement.

Chan JCY, Diakos CI, Chan DLH, Engel A, Pavlakis N, Gill A, Clarke SJ.

Ann Surg. 2018 Jun;267(6):1119-1125. doi: 10.1097/SLA.0000000000002251.

PMID:
28394869
36.

Histopathological tumour viability after neoadjuvant chemotherapy influences survival in resected pancreatic cancer: analysis of early outcome data.

Townend P, de Reuver PR, Chua TC, Mittal A, Clark SJ, Pavlakis N, Gill AJ, Samra JS.

ANZ J Surg. 2018 Mar;88(3):E167-E172. doi: 10.1111/ans.13897. Epub 2017 Mar 20.

PMID:
28318082
37.

The effect of anti-angiogenic agents on overall survival in metastatic oesophago-gastric cancer: A systematic review and meta-analysis.

Chan DL, Sjoquist KM, Goldstein D, Price TJ, Martin AJ, Bang YJ, Kang YK, Pavlakis N.

PLoS One. 2017 Feb 21;12(2):e0172307. doi: 10.1371/journal.pone.0172307. eCollection 2017. Review.

38.

The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials.

Li BT, Barnes TA, Chan DL, Naidoo J, Lee A, Khasraw M, Marx GM, Kris MG, Clarke SJ, Drilon A, Rudin CM, Pavlakis N.

Lung Cancer. 2016 Dec;102:21-27. doi: 10.1016/j.lungcan.2016.10.004. Epub 2016 Oct 17.

39.

Factors affecting whether or not cancer patients consider using acupuncture.

Oh B, Eade T, Kneebone A, Pavlakis N, Clarke S, Eslick G, River J, Back M.

Acupunct Med. 2017 Apr;35(2):107-113. doi: 10.1136/acupmed-2016-011115. Epub 2016 Sep 22.

PMID:
27658799
40.

Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target.

Selinger CI, Li BT, Pavlakis N, Links M, Gill AJ, Lee A, Clarke S, Tran TN, Lum T, Yip PY, Horvath L, Yu B, Kohonen-Corish MR, O'Toole SA, Cooper WA.

Histopathology. 2017 Feb;70(3):402-411. doi: 10.1111/his.13076. Epub 2016 Nov 15.

41.

Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma.

Wong MH, Xue A, Baxter RC, Pavlakis N, Smith RC.

Neoplasia. 2016 Jul;18(7):425-35. doi: 10.1016/j.neo.2016.06.001.

42.

Lutetium-177 DOTATATE Production with an Automated Radiopharmaceutical Synthesis System.

Aslani A, Snowdon GM, Bailey DL, Schembri GP, Bailey EA, Pavlakis N, Roach PJ.

Asia Ocean J Nucl Med Biol. 2015 Summer;3(2):107-15.

43.

Exhaled breath condensate for lung cancer protein analysis: a review of methods and biomarkers.

Hayes SA, Haefliger S, Harris B, Pavlakis N, Clarke SJ, Molloy MP, Howell VM.

J Breath Res. 2016 Jul 5;10(3):034001. doi: 10.1088/1752-7155/10/3/034001. Review.

PMID:
27380020
44.

Systematic Review and Meta-Analysis on the Role of Chemotherapy in Advanced and Metastatic Neuroendocrine Tumor (NET).

Wong MH, Chan DL, Lee A, Li BT, Lumba S, Clarke SJ, Samra J, Pavlakis N.

PLoS One. 2016 Jun 30;11(6):e0158140. doi: 10.1371/journal.pone.0158140. eCollection 2016. Review.

45.

Systemic therapies for advanced gastroenteropancreatic neuroendocrine tumors.

Patel D, Chan D, Cehic G, Pavlakis N, Price TJ.

Expert Rev Endocrinol Metab. 2016 Jul;11(4):311-327. doi: 10.1080/17446651.2016.1199952. Epub 2016 Jun 23.

PMID:
30058926
46.

Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial.

Pavlakis N, Sjoquist KM, Martin AJ, Tsobanis E, Yip S, Kang YK, Bang YJ, Alcindor T, O'Callaghan CJ, Burnell MJ, Tebbutt NC, Rha SY, Lee J, Cho JY, Lipton LR, Wong M, Strickland A, Kim JW, Zalcberg JR, Simes J, Goldstein D.

J Clin Oncol. 2016 Aug 10;34(23):2728-35. doi: 10.1200/JCO.2015.65.1901. Epub 2016 Jun 20.

47.

ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours.

Segelov E, Waring P, Desai J, Wilson K, Gebski V, Thavaneswaran S, Elez E, Underhill C, Pavlakis N, Chantrill L, Nott L, Jefford M, Khasraw M, Day F, Wasan H, Ciardiello F, Karapetis C, Joubert W, van Hazel G, Haydon A, Price T, Tejpar S, Tebbutt N, Shapiro J.

BMC Cancer. 2016 May 31;16:339. doi: 10.1186/s12885-016-2389-8.

48.

Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer.

Reid G, Kao SC, Pavlakis N, Brahmbhatt H, MacDiarmid J, Clarke S, Boyer M, van Zandwijk N.

Epigenomics. 2016 Aug;8(8):1079-85. doi: 10.2217/epi-2016-0035. Epub 2016 May 17. Review.

49.

Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study.

Segelov E, Thavaneswaran S, Waring PM, Desai J, Robledo KP, Gebski VJ, Elez E, Nott LM, Karapetis CS, Lunke S, Chantrill LA, Pavlakis N, Khasraw M, Underhill C, Ciardiello F, Jefford M, Wasan H, Haydon A, Price TJ, van Hazel G, Wilson K, Simes J, Shapiro JD.

J Clin Oncol. 2016 Jul 1;34(19):2258-64. doi: 10.1200/JCO.2015.65.6843. Epub 2016 Apr 25.

PMID:
27114605
50.

Systematic Review of the Role of Targeted Therapy in Metastatic Neuroendocrine Tumors.

Lee A, Chan DL, Wong MH, Li BT, Lumba S, Clarke SJ, Samra J, Pavlakis N.

Neuroendocrinology. 2017;104(3):209-222. doi: 10.1159/000446115. Epub 2016 Apr 16. Review.

Supplemental Content

Loading ...
Support Center